Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cytokinetics Inc

CYTK
Current price
51.94 USD -0.84 USD (-1.59%)
Last closed 52.78 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 086 536 704 USD
Yield for 12 month +45.65 %
1Y
3Y
5Y
10Y
15Y
CYTK
21.11.2021 - 28.11.2021

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Address: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

82.35 USD

P/E ratio

Dividend Yield

Current Year

+7 530 000 USD

Last Year

+94 588 000 USD

Current Quarter

+835 000 USD

Last Quarter

+1 672 000 USD

Current Year

-4 362 000 USD

Last Year

-146 225 000 USD

Current Quarter

-1 496 000 USD

Last Quarter

-4 663 000 USD

Key Figures CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -485 592 000 USD
Operating Margin TTM -15117.96 %
PE Ratio
Return On Assets TTM -36.66 %
PEG Ratio -0.42
Return On Equity TTM -572.15 %
Wall Street Target Price 82.35 USD
Revenue TTM 3 752 000 USD
Book Value -3.78 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -81.9 %
Dividend Yield
Gross Profit TTM -146 225 000 USD
Earnings per share -5.4 USD
Diluted Eps TTM -5.4 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CYTK

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:6
Payout Ratio
Last Split Date 25.06.2013
Dividend Date

Stock Valuation CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1013.0936
Price Sales TTM 993.8192
Enterprise Value EBITDA -16.7043
Price Book MRQ 31.8985

Financials CYTK

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CYTK

For 52 weeks

25.98 USD 110.25 USD
50 Day MA 60 USD
Shares Short Prior Month 14 191 794
200 Day MA 55.47 USD
Short Ratio 10.3
Shares Short 16 424 705
Short Percent 22.11 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics